Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib As Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Mieke Ptaszynski, Marie Payton, Marcia Farrow, Eric Feldman

Blood (2024) 144 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2024-204980

Published: 2024

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Jeffrey E Lancet, MD, Jorge E Cortes, MD, Tibor Kovacsovics, MD, Donna E. Hogge, MD, PhD, FRCPC, Jonathan E. Kolitz, MD, Martin S Tallman, MD, Antje Hoering, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Eric Feldman, MD

Blood (2012) 120 (21): 3626.

https://doi.org/10.1182/blood.V120.21.3626.3626

Published: 2012

Journal Articles

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Blood (2012) 120 (21): 414.

https://doi.org/10.1182/blood.V120.21.414.414

Published: 2012

Journal Articles

The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death

Isabelle Petit, Matthias A. Karajannis, Loic Vincent, Lauren Young, Jason Butler, Andrea T. Hooper, Koji Shido, Hermann Steller, David J. Chaplin, Eric Feldman, Shahin Rafii

Blood (2008) 111 (4): 1951–1961.

https://doi.org/10.1182/blood-2007-05-089219

Published: 2008

Includes: Supplemental data

Journal Articles

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

Jorge Cortes, MD, Gail J. Roboz, MD, Hagop Kantarjian, MD, Eric Feldman, MD, Judy Karp, MD, Allyson Pollack, Katrina Sandy, RN, Niranjan Rao, Shiro Akinaga, Mark Levis, MD

Blood (2007) 110 (11): 909.

https://doi.org/10.1182/blood.V110.11.909.909

Published: 2007

Journal Articles

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

Jia Ruan, MD, PhD, Morton Coleman, MD, Richard R. Furman, MD, Patricia Glynn, Maureen Joyce, Jamie Ketas, Ken Cheung, PhD, Sarah Church, Tsiporah Shore, MD, Eric Feldman, MD, Sarah Rutherford, Elizabeth Hyjek, MD, PhD, Amy Chadburn, MD, Shahin Rafii, MD, John P. Leonard, MD

Blood (2006) 108 (11): 2751.

https://doi.org/10.1182/blood.V108.11.2751.2751

Published: 2006

Journal Articles

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Ellen Ritchie, MD, Lia Gore, MD, Gail J. Roboz, MD, Eric Feldman, MD, Farhad Ravandi, MD, Richard Furman, MD

Blood (2006) 108 (11): 1881.

https://doi.org/10.1182/blood.V108.11.1881.1881

Published: 2006

Journal Articles

PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM).

Francis J. Giles, MD, Michael Carroll, MD, Alan List, MD, Alessandra Ferrajoli, MD, Deborah Thomas, MD, Jorge Cortes, MD, Eric Feldman, MD, Gail Roboz, MD

Blood (2006) 108 (11): 4920.

https://doi.org/10.1182/blood.V108.11.4920.4920

Published: 2006

Journal Articles

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

Blood (2006) 107 (1): 293–300.

https://doi.org/10.1182/blood-2005-06-2469

Published: 2006

Journal Articles

High-Dose Mitoxantrone-Based Induction Therapy in Newly-Diagnosed AML. Results of 171 Patients Treated at NYMC between 1991–2003.

Karen Seiter, MD, Delong Liu, MD, PhD, Eric Feldman, MD, Qiuhu Shi, PhD, Paul Baskind, Muhammad Arshad, MD, Anila Qureshi, MD, Tauseef Ahmed, MD

Blood (2005) 106 (11): 1859.

https://doi.org/10.1182/blood.V106.11.1859.1859

Published: 2005

Journal Articles

A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.

David A. Rizzieri, MD, Eric Feldman, MD, Joseph O. Moore, MD, Gail J. Roboz, MD, John F. DiPersio, MD, Nashat Gabrail, MD, Wendy Stock, MD, Victor M. Rivera, PhD, Maher Albitar, MD, Camille L. Bedrosian, MD, Francis Giles, MD

Blood (2005) 106 (11): 2980.

https://doi.org/10.1182/blood.V106.11.2980.2980

Published: 2005

Journal Articles

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, Eli Estey, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary Schiller, Virginia Klimek, Stephen D. Nimer, Alois Gratwohl, Chuna Ram Choudhary, Constan Mueller-Tidow, Hubert Serve, Harald Gschaidmeier, Pamela S. Cohen, Christoph Huber, Thomas Fischer

Blood (2005) 105 (1): 335–340.

https://doi.org/10.1182/blood-2004-02-0660

Published: 2005

Journal Articles

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Blood (2002) 99 (10): 3530–3539.

https://doi.org/10.1182/blood.V99.10.3530

Published: 2002

Journal Articles

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

Susan O’Brien, Hagop Kantarjian, Charles Koller, Eric Feldman, Miloslav Beran, Michael Andreeff, Sergio Giralt, Bruce Cheson, Michael Keating, Emil Freireich, Mary Beth Rios, Moshe Talpaz

Blood (1999) 93 (12): 4149–4153.

https://doi.org/10.1182/blood.V93.12.4149

Published: 1999

NARROW

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib As Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM).

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

High-Dose Mitoxantrone-Based Induction Therapy in Newly-Diagnosed AML. Results of 171 Patients Treated at NYMC between 1991–2003.

A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only